ArticleEuropean journal of nuclear medicine and molecular imaging2026
Scintigraphy for transthyretin cardiac amyloidosis diagnosis in Austria, Germany, and Switzerland from 2021 to 2024. A survey report.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SPECT and PET myocardial perfusion imaging in Austria, Germany, and Switzerland results of the 2nd joint survey 2024.European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBone scintigraphy using technetium-99 m-labelled phosphonates is increasingly applied for imaging of cardiac transthyretin (ATTR) amyloidosis. However, there is limited data on how frequently this technique is used. MATERIALS AND
methodsTo address this issue, we added questions about the number of patients referred for nuclear medicine scanning for suspected cardiac amyloidosis and the proportion of positive results (Perugini score of 2 or 3) to the 2024 survey on myocardial perfusion imaging conducted jointly in Germany, Austria and Switzerland.
resultsThe number of participating institutions in Austria, Germany and Switzerland was 12, 170 and 16, respectively. The number of patients scanned for cardiac amyloidosis was 1487, 4029 and 824 with a positivity-rate of 41%, 37% and 49%.
conclusionThe survey data reveal an increasing diagnostic effort for cardiac amyloidosis from 2021 to 2024, with a similar trend observed in all three countries. The average positivity rate in 2024 was almost 40% vs. about 33% in 2021. The results from 2021 to 2024 across all participants demonstrate improved pre-selection by the referring physicians but also increased awareness and improved training among nuclear medicine physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.